Trial Profile
Phase I, dose-escalating trial to evaluate the tolerability and pharmacokinetics of single ascending oral doses of NGX 426
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 02 Feb 2009
Price :
$35
*
At a glance
- Drugs Dasolampanel (Primary)
- Indications Migraine; Neuropathic pain
- Focus Adverse reactions
- Sponsors TorreyPines Therapeutics Inc